Denosumab, a chronically infected lower molar and the extraction decision
A 71-year-old woman is referred by her general dental practitioner for extraction of tooth 46. She has a 4-year history of denosumab 60 mg subcutaneously every 6 months for postmenopausal osteoporosis; her last injection was 10 weeks ago. She also takes calcium and vitamin D and has well-controlled type 2 diabetes (HbA1c 6.4%) and stage 3a chronic kidney disease (eGFR 55 mL/min/1.73 m²). She has never had radiotherapy to the jaws, has no history of MRONJ, and does not smoke. Tooth 46 is grade II mobile, has a buccal sinus discharging pus, probing depth 8 mm distally, and a periapical radiolucency. She is afebrile and has no facial swelling. She asks whether she should 'just stop the denosumab for a few months' so the extraction is safer. The referral letter asks you to manage the tooth in primary care.
1. How would you stratify this patient's MRONJ risk, and what treatment options would you discuss with her?
Read the worked answer
She is not automatically high risk, but she is not no-risk. Relevant factors are denosumab for 4 years, diabetes, CKD, and active chronic infection. She lacks the highest-risk features: malignancy, IV antiresorptive therapy, radiotherapy, corticosteroids, smoking, or previous MRONJ. That places her in a low-to-moderate risk category for oral surgery, but extraction is still a recognised trigger.
Options to discuss:
- Retain and manage the infection with drainage, root canal treatment, and restoration. This may be unrealistic because 46 is grade II mobile with an 8 mm pocket and a sinus; retention has a guarded prognosis and may simply defer the problem.
- Extraction in primary care with an atraumatic technique, if you are confident in the risk assessment and can provide close follow-up. This includes minimal periosteal trauma, primary closure, and avoiding tight sutures.
- Refer to oral surgery if there is diagnostic doubt, if the tooth is complex, or if the patient prefers specialist care.
The decision should be shared and documented, not based on the drug alone.
2. What advice would you give about stopping denosumab, and who should be involved?
Read the worked answer
I would advise her not to stop denosumab herself. There is no reliable evidence that a drug holiday reduces MRONJ risk, and stopping denosumab can cause rebound bone loss and vertebral fractures. The timing of the last dose is not a reason to delay urgent treatment indefinitely.
The correct approach is to liaise with her GP and the clinician who prescribed denosumab (often rheumatology or endocrinology). Explain the planned extraction, her risk factors, and the lack of evidence for a drug holiday. If the specialist recommends a delay or an alternative, coordinate the date and record that advice. Do not imply that stopping the drug will make the extraction risk-free.
Document the discussion, the patient's preference, and the fact that the decision was shared. If she elects to proceed, give her written warning signs of MRONJ and arrange early review.
3. Outline the consent discussion and post-extraction follow-up you would arrange.
Read the worked answer
Consent should cover the risk of MRONJ, however small, and the fact that the true risk is uncertain. Explain the alternative of retaining the tooth, the likely failure of that option, and the consequences of untreated infection. Mention bleeding, bruising, swelling, trismus, dry socket, and the possibility of a further procedure. Record that she understands the MRONJ warning signs.
Post-operatively:
- Atraumatic extraction, gentle debridement, and primary closure where possible.
- Avoid smoking and trauma from dentures; reinforce oral hygiene.
- Analgesia and, only if clinically indicated, antibiotics for spreading infection.
- Review at 1–2 weeks and again at 8 weeks to check mucosal healing.
- Advise her to report persistent exposed bone, pain, swelling, or non-healing immediately.
Good records should include the risk discussion, liaison with the prescriber, the technique used, and the follow-up plan.